Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight loss and obesity drugs. Read more here.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on sales in recent quarters.

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting a profit of $22.86 per share, according to data compiled by LSEG. Quarterly sales of diabetes drug Mounjaro came in at $3.53 billion, compared with analysts expectations of $4.27 billion.

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.